Introduction
Myoclonic epilepsy with ragged-red fibers (MERRF) syndrome is a rare syndromic mitochondrial disorder (MID) with a broad range of clinical manifestations (Table 1 ) and a less heterogeneous genotype [1] . MERRF is most frequently due to mutations in the tRNA(Lys) gene (m.8344A > G, m.8356T > C, m.8363G > A) [2] but rarely also due to mutations in the MT-TL1/tRNA(Leu) (m.3291T > C) [3, 4] , tRNA(Ile) (m.4279A > G) [5] , MT-TF/tRNA(Phe) [6] , or MT-TP/tRNA(Pro) [7] genes respectively. Clinically, MERRF does not only manifest with epilepsy and myopathy but also with abnormalities of the eyes, ears, endocrine organs, heart, gastrointestinal tract, and the skin (Table 1) . However, epilepsy is the most prevalent manifestation of MERRF and requires particular attention since it is a dominant feature of the phenotype and difficult to treat. This review aims at summarising and discussing current and previous findings concerning the management of epilepsy in MERRF patients.
Methods
Data for this review were identified by searches of MEDLINE, Current Contents, EMBASE, Web of Science, Web of Knowledge, LILACS, SCOPUS, and Google Scholar for references of relevant articles. Search terms used for these databases were "MERRF", "myoclonic epilepsy with ragged-red fibers", or "m.8344A > G", combined with "epilepsy", "seizures", "antiepileptic drugs", and "antiepileptic treatment". Results of the search were screened for potentially relevant studies by application of inclusion and exclusion criteria for the full texts of the relevant studies. Included were randomized controlled trials (RCTs), observational studies with controls, case series, and case reports. Reviews, editorials, and letters were not included. Only original articles about humans, and published between 1966 and 2016 were included. Reference lists of retrieved studies were checked for reports of additional studies.
Results

Literature search
By searching the literature according to the criteria mentioned above, the number of hits achieved was 504. By filtering these results through exclusion of articles on non-human subjects, of letters, and of editorials, and exclusion of articles in a language inaccessible to translation, the number was reduced to 104 hits. After studying the abstracts, 93 were selected for detailed studying but only 64 were accessible as full papers and thus included in the list of References
Types of seizures reported in MERRF syndrome
Myoclonic epilepsy in MERRF is part of the group of progressive myoclonic epilepsies, which additionally include UnverrichtLundborg disease, Lafora disease, various types of neuronal ceroid lipofuscinoses, and sialidoses type 1 and 2. The most frequent seizure type in MERRF is generalised myoclonic seizure (Table 2 ) [1] . Other types of seizures reported in MERRF include focal myoclonic, focal atonic, focal clonic, generalised tonic-clonic, generalised atonic, generalised myoclonic-atonic, typical absences [8] , myoclonic absences, or tonic-clonic of unknown onset seizures (Table 2) [2, 9, 10, 11, 12, 13] . Some patients may develop status epilepticus [9] . Myoclonus in MERRF may be constant or intermittent, photosensitive, or intensified by action (writing, eating) [12] . Myoclonic jerks in MERRF may correlate with electroencephalographic spike or polyspike activity, and there may be suppression of epileptic activity upon eye opening [12] . Myoclonus in MERRF may not only be the clinical manifestation of epileptic activity but also due to cerebellar dysfunction [14] .
AEDs for epilepsy in MERRF syndrome
There are no specific recommendations available about the treatment of epilepsy in MERRF syndrome. However, general recommendations for the treatment of mitochondrial epilepsy have been repeatedly reported [15, 16, 17, 18, 19] and several expert opinions have been published (Table 3) .
Classical antiepileptic drugs
Tonic-clonic seizures may be easy to treat but treatment of myoclonus may be challenging [12] . Some authors recommend clonazepam or zonisamide for myoclonus in MERRF syndrome [20] . However, these antiepileptic drugs (AEDs) have been only rarely applied in clinical practice. By means of a PubMed search clonazepam was mentioned only 3 times in association with MERRF syndrome and zonisamide was mentioned only once (Table 3) .
Concerning the recommendation of lamotrigine for myoclonic epilepsy [20] , there are no studies or reports about the application of lamotrigine in MERRF syndrome available. On the contrary, there are studies showing that lamotrigine may even aggravate myoclonus [21] . Other AEDs which have been reported to aggravate myoclonus include phenytoin, carbamazepine, oxcarbazepine, vigabatrin, tiagabine, gabapentin, and pregabalin (Table 3 ) [21] . AEDs which are commonly used for myoclonic epilepsy in general include valproate, clonazepam, phenobarbital, or primidone [21] . Among the novel AEDs, levetiracetam, topiramate, zonisamide, and piracetam are the ones recommended by experts [21] . Whether perampanel or rufinamide has a beneficial effect on epilepsy in MERRF patients has not been investigated yet. There are no reports about the application of perampanel or rufinamide in MERRF syndrome particularly for myoclonic epilepsy (Table 3) . However, perampanel and rufinamide have been successfully applied in non-mitochondrial myoclonic epilepsy (Table 3) . Today, the most frequently applied AED for epilepsy in MERRF seems to be levetiracetam [1] . However, even levetiracetam may be ineffective in some cases. In a 71yo female with MERRF syndrome due to the mutation m.8344A > G myoclonic seizures did only respond to piracetam [2] . Oxcarbazepine, levetiracetam, and lamotrigine were ineffective in this patient. AEDs which have not been reported to have been used in MERRF patients include carbamazepine, phenytoin, phenobarbital, primidone, rufinamide, perampanel, lacosamide, pregabalin, vigabatrin, tiagabine, felbamate, oxcarbazepine, ethosuximide, topiramate, gabapentin, and zonisamide.
Mitochondrion-toxicity of antiepileptic drugs
Concerning the mitochondrion-toxicity of AEDs, it has to be considered that some of the AEDs recommended for myoclonic epilepsy have been proven mitochondrion-toxic, why they should not be applied. as first line AEDs in mitochondrial epilepsy in general. AEDs with the strongest mitochondrion-toxic effect include valproic acid, carbamazepine, phenytoin, and phenobarbital [22] . Valproic acid causes complex-I and complex-IV dysfunction [23, 24] , reduces state-3 respiration and ATP production, sequesters cytochrome-aa3 and coenzyme-A, inhibits key enzymes of the beta oxidation [22] , and results in impaired organisation of the inner mitochondrial membrane and secondary carnitine-deficiency [22] , why it should be avoided in MERRF patients. Carbamazepine inhibits the mitochondrial ATPase and thus reduces ATP production, state-3 respiration, and the mitochondrial membrane potential, increases state-4 respiration, and impairs calcium uptake/release [25] . Phenobarbital inhibits complex-I, reduces ATP synthesis, state-3 respiration, and the mitochondrial membrane potential, increases state-4 respiration, and impairs the calcium uptake/release [22] . Phenytoin inhibits the mitochondrial Na/K-ATPase and the Mg-ATPase, reduces ATP synthesis, state-3 respiration, and the mitochondrial membrane potential, increases state-4 respiration, and impairs the calcium uptake/release [25] . Accordingly, effective AEDs for myoclonic epilepsy in MIDs include levetiracetam, piracetam, zonisamide, topiramate, benzodiazepines, and possibly perampanel.
Alternative strategies for treating epilepsy in MERRF
Occasionally, myoclonic epilepsy or myoclonic status epilepticus may be refractory to conventional AEDs [20] . In this case, alternative therapeutic options should be considered, such as the ketogenic diet, L-tryptophan [26] , N-acetyl-cysteine, vagal nerve stimulation, deep brain stimulation, or epilepsy surgery [21] . Additionally, coenzyme-Q has been reported to exhibit a beneficial effect on mitochondrial epilepsy in mice [27] . Coenzyme-Q was also effective in myoclonic epilepsy due to primary coenzyme-Qdeficiency [27] . Since MERRF occasionally may go along with stroke-like episodes (SLEs) [28] and since SLEs may go along with seizures before, during, or after a SLE [29] , MERRF patients should be investigated prospectively for current or previous stroke-like lesions, the morphological equivalent of a SLE. In case seizures are associated with SLEs, NO-precursors, such as L-arginine or Lcitrulline might be beneficial for epilepsy in MERRF. Structural cerebral lesions in MERRF in addition to stroke-like lesions, which could be associated with epilepsy include atrophy or white matter lesions [30] . Vagal nerve stimulation, deep brain stimulation, or epilepsy surgery have not been carried out in a MERRF patient so far but vagal nerve stimulation has been shown beneficial in patients with myoclonic astatic epilepsy [31] .
Conclusions
Mitochondrial epilepsy not only occurs in MERRF syndrome but in a number of other syndromic and non-syndromic MIDs [15, 32] . Among epilepsies in MIDs, myoclonic epilepsy is the one most prominent in MERRF syndrome. Among MIDs, myoclonic epilepsy not only occurs in MERRF syndrome but also in AlpersHuttenlocher disease, in coenzyme-Q deficiency, and various non-specific, syndromic MIDs [14] . Currently, treatment of epilepsy in MERRF follows recommendations of experts since no cohort studies on the effectivity of AEDs or other antiepileptic Nr: not reported, bf: beneficial, *: reports with beneficial or no effect.
measures have been carried out so far. AEDs which are most frequently recommended for epilepsy in MERRF include levetiracetam, piracetam, zonisamide, topiramate, and benzodiazepines. Generally, any mitochondrion-toxic agents, including mitochondrion-toxic AEDs, should be avoided in MIDs, including MERRF. Additionally, AEDs potentially enhancing the frequency of myoclonic seizures should not be given to these patients.
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